Compare AVXL & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVXL | XGN |
|---|---|---|
| Founded | 2004 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.9M | 110.7M |
| IPO Year | 2013 | 2014 |
| Metric | AVXL | XGN |
|---|---|---|
| Price | $1.26 | $8.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $10.57 |
| AVG Volume (30 Days) | ★ 1.2M | 331.1K |
| Earning Date | 11-24-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $11.02 |
| Revenue Next Year | N/A | $10.28 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.13 | $2.59 |
| 52 Week High | $7.60 | $10.83 |
| Indicator | AVXL | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 27.79 | 54.61 |
| Support Level | $1.14 | $7.81 |
| Resistance Level | $1.60 | $8.94 |
| Average True Range (ATR) | 0.10 | 0.54 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 14.89 | 70.49 |
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.